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growth-promoting receptor with high 
n to one with low n and show that 
hyperbolic responses to increasing 
UDP-GlcNAc become switch-like. 
This requires removing N-glycan 
sites that are not required for fold-
ing and trafficking, a feat that may be 
difficult. Another prediction would 
be that overexpression of the UDP-
GlcNAc transporter should cause all 
responses to occur at lower concen-
trations of GlcNAc. Galectin-3 and 
Mgat5 double-knockout mice should 
be investigated, although there are 
15 galectins, and redundancy may 
be a problem. The predicted differ-
ential strength of receptor associa-
tions with the galectin lattice should 
be tested directly by photobleach-
ing experiments and the galectin-
3 lattice visualized under different 
growth conditions. Finally, it will be 
important to use mass spectrometry 
with heavy isotopes to prove that the 
increase in intracellular UDP-GlcNAc 
does indeed lead to the production 
of more highly branched N-glycans. 
These experiments will undoubt-
edly be forthcoming. Meanwhile, in 
an experimental tour de force, Lau 
et al. (2007) have identified a new 
paradigm for fine-tuning the regula-
tion of cell growth and differentiation 
in mammals by a mechanism that 
involves the regulation of receptor 
signaling by N-glycan site number 
and N-glycan branching controlled 
by metabolic flux.
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The hypoxia-inducible factor HIF-1 is known to promote anaerobic respiration during low 
oxygen conditions (hypoxia). In this issue, Fukuda et al. (2007) expand the range of HIF-1’s 
functions by showing that it modulates aerobic respiration as well.It has been known since the time of 
Pasteur that cells in low oxygen con-
ditions switch from aerobic to anaero-
bic metabolism. More recently, it has 
become clear that the hypoxia-induc-
ible factor 1 (HIF-1) is a key oxygen 
sensor that mediates the cell’s ability 
to cope with decreased oxygen. HIF-1 
is a transcriptional activator that is sta-bilized when oxygen concentrations in 
the cell are low. It upregulates glyco-
lytic enzymes and glucose transport-
ers, thereby allowing the cell to depend 
more heavily on the anaerobic process 
of glycolysis for energy. In this issue, 
Semenza and colleagues (Fukuda et al., 
2007) reveal that HIF-1 unexpectedly 
also modulates aerobic metabolism.Cell Fukuda et al. (2007) show that in 
hypoxic conditions, the HIF-1 tran-
scription factor regulates the replace-
ment of a key subunit of the cyto-
chrome oxidase complex (the last 
complex in the electron transport 
chain also known as complex IV) to 
maximize the efficiency of mitochon-
drial respiration. In this manner HIF-1 129, April 6, 2007 ©2007 Elsevier Inc. 29
figure 1. HIf-1 enhances Aerobic Respiration during Hypoxia
Under normal oxygen concentrations (normoxia), COX4-1 is the predominant isoform of COX4 
present in complex IV of the electron transport chain, which transfers electrons to oxygen. During 
hypoxia, the absence of sufficient amounts of oxygen results in the production of reactive oxygen 
species (such as H2O2) that are harmful to the cell. Fukuda et al. (2007) reveal that under hypoxic 
conditions, HIF-1 activates the LON protease to degrade COX4-1 and also upregulates COX4-2 
to replace COX4-1 in complex IV. COX4-2 is more efficient at facilitating the transfer of electrons 
to oxygen and thereby protects the cell from oxidative damage during hypoxia. Interestingly, 
forced expression of the more efficient COX4-2 under normoxic conditions results in the genera-
tion of more reactive oxygen species and an increase in caspase activity (Fukuda et al., 2007), 
which may be why COX4-2 is not the predominant isoform in complex IV.promotes the efficient use of available 
oxygen while also reducing the gener-
ation of harmful byproducts of respira-
tion such as free radicals and H2O2.
High-energy electrons from the 
tricarboxylic acid (TCA) cycle are 
passed through the four complexes 
of the electron transport chain, pow-
ering the buildup of a proton gradi-
ent across the mitochondrial inner 
membrane space. As part of complex 
IV, cytochrome oxidase transfers 
the electrons to oxygen. Complex 
IV resides in the inner mitochondrial 
membrane and is made up of 13 
polypeptides (COX subunits), some 
of which have multiple isoforms and 
are subject to regulation. COX4 has 
two isoforms: COX4-1 and COX4-2.
In an elegant study in mammalian 
cells, Fukuda et al. (2007) specifically 
describe how the composition of 
complex IV changes in the face of low 
oxygen. The authors showed that dur-
ing hypoxia, HIF-1 upregulates COX4-
2 expression while also activating the 
gene for the LON mitochondrial pro-
tease, which in turn degrades COX4-
1. This facilitates the swapping of 
subunit COX4-1 for the more efficient 
subunit COX4-2, thereby enhancing 
mitochondrial respiration (Fukuda et 
al., 2007; Figure 1).
The enhancement of mitochondrial 
respiration during hypoxia by swap-30 Cell 129, April 6, 2007 ©2007 Elsevierping cytochrome oxidase subunits 
has been demonstrated previously in 
yeast (Waterland et al., 1991; Allen et 
al., 1995). However, the mechanism 
that mediates the swapping in yeast 
does not hinge on HIF-1, and there is 
in fact no HIF-1 homolog in yeast. The 
mechanism in yeast is tied to oxygen 
concentration more indirectly: the 
Hap2/3/4/5 and Hap1 proteins are 
activated by binding heme, and heme 
is only produced in aerobic condi-
tions. Hap2/3/4/5, in turn, transac-
tivates the COX5 isoform COX5a 
(COX5 is the yeast counterpart of 
mammalian COX4). At the same 
time, Hap1 activates Rox1, which 
represses the COX5b isoform. So in 
normal oxygen conditions, the less 
efficient COX5a predominates. Dur-
ing hypoxia, the activation of COX5a 
is lost, and the repression of COX5b 
is relieved. Thus, the more efficient 
subunit COX5b takes over for COX5a 
to enhance respiration during hypoxia 
(Burke and Poyton, 1998). The mam-
malian version described by Fukuda 
et al. (2007) is similar in concept 
and involves the same two homolo-
gous subunits of complex IV but is 
regulated quite differently. However, 
the end result is a clear example of 
convergent evolution within the com-
munity of single and multicellular 
eukaryotes. Inc.Tumors are able to survive in 
hypoxic conditions, and pharmaco-
logical inhibition of HIF-1 is being 
explored currently as an anticancer 
therapy. Inhibition of the subunit 
switch described by Fukuda et al. 
(2007) could be used therapeutically 
to further inhibit a tumor’s ability 
to survive in hypoxia. More specifi-
cally, one could inhibit or inactivate 
COX4-2 and/or the LON protease 
to achieve strategic modulation of 
tumor metabolism.
The data presented here nicely 
complement that published last 
year showing that HIF-1 expression 
increased pyruvate dehydrogenase 
kinase levels, acting to inhibit pyru-
vate dehydrogenase and thus pre-
vent entry of pyruvate into the TCA 
cycle (Kim et al., 2006; Papandreou 
et al., 2006). Thus, it is clear that 
HIF-1 is acting across the metabolic 
spectrum, increasing glucose trans-
port into the cell, ramping up glycoly-
sis, and fine-tuning respiration in the 
mitochondria.
What is perhaps most remarkable 
is that the same system responsible 
for this metabolic adaptation also 
modulates such a wide range of other 
organismal reactions to hypoxia, 
including physiological responses 
that arose much later in evolution, 
e.g., erythropoiesis and angiogen-
esis. One could argue that evolution 
found a very useful tool in HIF-1 early 
on and has continued to use it when-
ever short of breath.
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